Stockscreener 앱 받기
4.99
3.74%
0.18
전일 마감가:
$4.81
열려 있는:
$4.9242
하루 거래량:
1.20M
Relative Volume:
1.16
시가총액:
$365.50M
수익:
$31,000
순이익/손실:
$-38.18M
주가수익비율:
-7.1184
EPS:
-0.701
순현금흐름:
$-38.90M
1주 성능:
-0.99%
1개월 성능:
-3.67%
6개월 성능:
-5.31%
1년 성능:
-39.29%
1일 변동 폭
$4.88
$5.13
1주일 범위
$4.785
$5.17
52주 변동 폭
$4.25
$8.20
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.99 | 352.32M | 31,000 | -38.18M | -38.90M | -0.701 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel gains on additional mid-stage trial data for lead asset - MSN
Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Barchart
Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares - Stock Titan
Buy Signal: Should I hold or sell Candel Therapeutics Inc nowQuarterly Investment Review & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data By Investing.com - Investing.com Australia
Will Candel Therapeutics Inc outperform small cap indexesWall Street Watch & Weekly High Conviction Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data - Investing.com
Candel Therapeutics prices $100M public offering at $5.45 per share - MSN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Market movers: Uber, Getty Images, Candel Therapeutics... - Proactive Investors
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Proactive financial news
Candel reports extended survival data for lung cancer therapy - Investing.com
Candel Therapeutics Inc extended survival tail observed in trial of aglatimagene besadenovec - marketscreener.com
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Bitget
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (Can-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - marketscreener.com
Aug Drivers: Is Candel Therapeutics Inc stock forming a triangle pattern2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
FY2030 Earnings Forecast for CADL Issued By HC Wainwright - MarketBeat
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7% - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL) - The Globe and Mail
Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL - MarketBeat
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - The Globe and Mail
Responsive Playbooks and the CADL Inflection - Stock Traders Daily
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00 - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Yahoo Finance
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Candel Therapeutics, Inc. announces financial results for the fourth quarter and full year of fiscal 2025, along with recent strategic updates. - Bitget
CADL: Pivotal trials and BLA submission planned for 2026, with strong financial runway into 2028 - TradingView
BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million - TradingView
Funding extends Candel Therapeutics (NASDAQ: CADL) cash runway into early 2028 - Stock Titan
Tech Rally: Is Candel Therapeutics Inc stock suitable for long term investing2026 Momentum Check & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research - MarketBeat
Candel Therapeutics Presents New Data From Phase 3 Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer - marketscreener.com
Candel Therapeutics Back On The Radar As Prostate And Lung Cancer Trial Catalysts Approach - RTTNews
Candel Therapeutics to present Phase 3 prostate cancer data at AUA 2026 - Proactive Investors
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - Bitget
Candel Therapeutics To Present New Data after Extended - GlobeNewswire
Gainers Report: How Candel Therapeutics Inc. stock compares to market leadersWeekly Market Report & Growth Focused Investment Plans - Naître et grandir
Moving Averages: Will Candel Therapeutics Inc. stock outperform Nasdaq indexJuly 2025 Selloffs & Smart Allocation Stock Tips - Naître et grandir
Candel Therapeutics (CADL) Projected to Post Earnings on Thursday - MarketBeat
CADL SEC FilingsCandel Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Candel Therapeutics, Inc. showcases linoserpaturev immunotherapy progress in recurrent glioblastoma case - Traders Union
United StatesGoodwin Guides Candel Therapeutics On $100 Million Public Offering And $100 Millon Royalty Funding Agreement With RTW - Mondaq
CADL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):